News

What is new in research on schizophrenia?

In this CME, learn more about the pathophysiology of HIV-associated neurocognitive disorder and to review the research and various tools used to aid in the diagnosis.

One doctor shares his story of becoming a community psychiatrist.

Did you miss the 2023 Annual Psychiatric Times World CME Conference? Don't worry, we've got you covered.

Here's how the Jewish stereotype of the hooked nose represents a greater problem: the resurgence of anti-Semitism.

Initial data from phase 2 safety profile for psilocybin in the treatment of PTSD indicates the treatment is well-tolerated.

"As I continue my medical sojourn, I am reminded that the world of health care is as diverse as the patients it serves."

Could fish oil replace antidepressants as a first-line pill for depression?

The ATA published these principles “to ensure trustworthy development, integration, and utilization of AI in order to maximize its potential benefits as a meaningful tool for patients and providers.”

"This letter I write from the heavenly ashes wishing that ebony and ivory twirl as one into the arms of divine humanity."

A transgender psychiatrist, open about her gender transition to patients and the public, just died.

Psychiatric treatment works to a degree comparable to other branches of medicine which address complex, chronic illnesses.

"A hundred skaters in Christmas red circle the lake..."

50 years ago, we stopped referring to homosexuality as a mental illness. Where are we now?

From a new look at the famous STAR*D study to updates from the National Academy of Sciences Conference on Adult ADHD, here are highlights from the week in Psychiatric Times.

What are the cardiometabolic risks of polypharmacy with quetiapine and long-acting injectable paliperidone in patients with schizophrenia?

What is new in research on ADHD?

Updates from Day 2 at the National Academy of Sciences Conference on adult ADHD.

The color of the year is…

“This is the first study to assess the standalone drug effects of MM-120 in the absence of any psychotherapeutic intervention.”

Happy holidays from the Psychiatric Times family!

John A. Talbott, MD: More than just a community psychiatrist.

How can we help refugee youth engage in positive coping strategies and heal from their trauma?

Wishing you light this holiday season!

Check out these updates for the National Academy of Sciences Conference on adult ADHD, including new research, thoughtful discussions, and more!

Since 2006, STAR*D stands out as an icon guiding treatment decisions of major depressive disorder. But what if it is broken?

MAPS has submitted an NDA for MDMA-assisted therapy for patients with posttraumatic stress disorder.

These important findings on esketamine nasal spray as a treatment for young individuals with suicidal ideation were presented at the ACNP 2023 Annual Meeting. We interviewed the vice president and head of neuropsychiatry clinical development at Johnson & Johnson Innovative Medicine to learn more.

A eulogy for an entertainer.